Literature DB >> 6154706

Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein.

D M Kerbiriou, B N Bouma, J H Griffin.   

Abstract

Human plasm contains at least two distinct kininogens, designated high Mr and low Mr kininogens, that differ in their Mr and susceptibility to different kallikreins. By limited proteolysis, plasma kallikrein cleaves high Mr kininogen to liberate kinin and gives a molecule containing two disulfide-linked polypeptide chains. Following reduction and alkylation of the two-chain molecule, the heavy chain and the light chain were isolated, and antisera were raised in goats against the alkylated heavy and light chains. The anti-heavy chain antiserum immunoprecipitated both high Mr and low Mr kininogen, whereas the anti-light chain antiserum was specific for high Mr kininogen. Thus, the heavy chain of kinin-free high Mr kininogen and low Mr kininogen extensively share identical immunologic determinants. In contrast, the immunologic determinants of the isolated light chain are unique to high Mr kininogen. Using immunochemical techniques, it was shown that high Mr kininogen or the light chain derived from it forms a complex either with prekallikrein or with kallikrein. Titrations of prekallikrein or kallikrein with increasing amounts of either high Mr kininogen or its alkylated light chain indicated that the complexes contain equimolar amounts of each molecule. These results show that a single site for prekallikrein or kallikrein binding to high Mr kininogen resides in the light chain region of the molecule.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154706

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Localisation of immunoreactive kininogen and tissue kallikrein in the human nephron.

Authors:  C D Figueroa; A G MacIver; J C Mackenzie; K D Bhoola
Journal:  Histochemistry       Date:  1988

2.  Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency.

Authors:  B N Bouma; D M Kerbiriou; J Baker; J H Griffin
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

3.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

4.  Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI.

Authors:  D Sinha; F S Seaman; A Koshy; L C Knight; P N Walsh
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

5.  Kinetic analysis of the interaction of human tissue kallikrein with single-chain human high and low molecular weight kininogens.

Authors:  M Maier; K F Austen; J Spragg
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

6.  Activation of latent collagenase by serum proteinases that interact with immobilized immunoglobulin G.

Authors:  P C Armour; S Levi; E E Golds; A R Poole; J S Mort; P J Roughley
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

7.  Binding of high-molecular-mass kininogen to the Apple 1 domain of factor XI is mediated in part by Val64 and Ile77.

Authors:  F S Seaman; F A Baglia; J A Gurr; B A Jameson; P N Walsh
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

8.  Inactivation of kallikrein in human plasma.

Authors:  F van der Graaf; J A Koedam; B N Bouma
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

9.  Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.

Authors:  C F Scott; M Schapira; H L James; A B Cohen; R W Colman
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

10.  Structural requirements for the procoagulant activity of nucleic acids.

Authors:  Julia Gansler; Miriam Jaax; Silke Leiting; Bettina Appel; Andreas Greinacher; Silvia Fischer; Klaus T Preissner
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.